Funding
Funding not disclosed
Founders
Product
Problem
Traditional medical research and drug discovery processes often face challenges in efficiently analyzing vast amounts of diverse medical data to identify disease patterns and therapeutic solutions. The process of identifying potential drug candidates and understanding their mechanisms of action can be time-consuming and costly, hindering the progress of personalized medicine.
Solution
Topazium offers an AI-powered platform that analyzes aggregated, anonymized medical records to accelerate medical research and drug discovery. The platform, driven by Artificial Medical Intelligence (AMI), integrates diverse data types, including chemical, genetic, epigenetic, medical imaging, and clinical information, to uncover hidden disease patterns and identify therapeutic solutions. Topazium provides researchers with in silico hypothesis testing, ingredient discovery, molecular pathway analysis, drug repurposing, virtual screening, molecular modeling, and virtual target identification. The platform offers its services through SaaS, IaaS, and a custom Algorithmic Factory, enabling researchers and physicians to move beyond the constraints of traditional medical research.
Target Audience
The primary target audience includes academic institutions, hospitals, health insurers, pharmaceutical and biotech companies, nutraceutical firms, wellness centers, and medical device manufacturers.
Features
- AI-driven analysis of diverse medical data types (chemical, genetic, epigenetic, medical imaging, and clinical)
- Identification of pathophysiological processes that drive certain diseases
- Discovery and classification of new chemical entities
- Prediction of specific target-binding affinities or drug-like properties
- Identification of chemical structures associated with certain toxic effects
- Prediction of unexpected human toxicity
- Selection of drug candidates for clinical trials
- Early identification of subpopulations at a higher risk of certain diseases
- Matching drugs no longer used with new clinical indications
- Prediction of "super-response" to specific drugs
- Monitoring quality of life and lifestyle changes
- IngrID (Ingredient Identifier) for matching food ingredients to achieve specific nutritional benefits
- GeneSight for uncovering the molecular pathways driving the physiological effects of chemical compounds
- TNDR (Topazium Network for Drug Repurposing) for connecting chemical compounds to diseases through advanced neural networks
- Virtual Screening for identifying compounds with the highest likelihood of interacting with a specific therapeutic target
- Virtual Docking for exploring interactions between candidates and specific targets
- Virtual Target Identification for uncovering proteins consistently linked to the onset of pathological conditions
- Biological Age Predictor for estimating a subject’s biological age from routine laboratory tests’ outputs
- Skinguard for assisting healthcare professionals in improving their skills for detecting skin cancer
- HADES a predictive scoring system crafted to facilitate the early detection of hereditary angioedema